Development of Intermediate-Temperature Solid Oxide Fuel Cells for Direct Utilization of Hydrocarbon Fuels

In this study, we compare the performance of SOFC having composite Cu-based anodes but made with the following low-temperature electrolytes: samaria-doped ceria (SDC), Sr- and Mg-doped lanthanum gallate (LSGM), and scandia-stabilized zirconia (ScSZ). Performance (V-I) curves and impedance spectra were measured using H2 and n-butane fuels at 973 K. The results suggest that the use of electrolyte materials with higher ionic conductivity can lead to improved anodes for direct-utilization SOFC, although the performance of each of the cells in n-butane appears to be at least partially limited by the electrochemical oxidation reaction

Anodes for Direct Oxidation of Hydrocarbons in Solid Oxide Fuel Cells

In this paper we describe the development of Cu/CeO2/YSZ anodes for solid oxide fuel cells (SOFCs) that are active for the direct electrochemical oxidation of dry hydrocarbon fuels. A novel method for synthesizing thin-electrolyte, anode-supported cells is described. This method uses tape-casting of YSZ layers with graphite pore formers, followed by impregnation with aqueous solutions of Cu(NO3)2 and Ce(NO3)2. The performance of model SOFCs with Cu/CeO2/YSZ anodes while operating on a variety of dry hydrocarbon fuels, including methane, butane, decane, and synthetic diesel is reported

CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice

Neuroinflammation and microglial activation are significant processes in Alzheimer’s disease pathology. Recent genome-wide association studies have highlighted multiple immune-related genes in association with Alzheimer’s disease, and experimental data have demonstrated microglial proliferation as a significant component of the neuropathology. In this study, we tested the efficacy of the selective CSF1R inhibitor JNJ-40346527 (JNJ-527) in the P301S mouse tauopathy model. We first demonstrated the anti-proliferative effects of JNJ-527 on microglia in the ME7 prion model, and its impact on the inflammatory profile, and provided potential CNS biomarkers for clinical investigation with the compound, including pharmacokinetic/pharmacodynamics and efficacy assessment by TSPO autoradiography and CSF proteomics. Then, we showed for the first time that blockade of microglial proliferation and modification of microglial phenotype leads to an attenuation of tau-induced neurodegeneration and results in functional improvement in P301S mice. Overall, this work strongly supports the potential for inhibition of CSF1R as a target for the treatment of Alzheimer’s disease and other tau-mediated neurodegenerative diseases

Inflammatory biomarkers in Alzheimer's disease plasma

Introduction:Plasma biomarkers for Alzheimer’s disease (AD) diagnosis/stratification are a“Holy Grail” of AD research and intensively sought; however, there are no well-established plasmamarkers.Methods:A hypothesis-led plasma biomarker search was conducted in the context of internationalmulticenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL;259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed.Results:Ten analytes showed significant intergroup differences. Logistic regression identified five(FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD andCTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI(AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Twoanalytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71).Discussion:Plasma markers of inflammation and complement dysregulation support diagnosis andoutcome prediction in AD and MCI. Further replication is needed before clinical translatio